Evaluation
*
*

Thinking about the impact of this session on your patients, please offer an estimate of the:

*
%
*
/month
*
1 (Disagree)2345 (Agree)
Describe the mechanism of action of novel extended adjuvant therapies for early HER2-positive breast cancer
Utilize evidence-based strategies for prophylaxis of diarrhea and other side effects
Comment on optimizing patient selection for treatment with extended adjuvant therapies
Implement HER2 status testing in accordance with the latest clinical practice guidelines
*
1 (Low)2345 (High)
G. Thomas Budd, MD
Wendy H. Vogel, MSN, FNP, AOCNP
*
*